Analyst firms · Oppenheimer · MDT
Oppenheimer MDT price target and rating history
Medtronic plc. (MDT) · Health Care
Oppenheimer rates Medtronic plc. (MDT) Perform with a $94 price target, as of its latest action on Aug 21, 2024. It has published 4 rating actions on MDT since November 2021, including 0 upgrades and 1 downgrade. Across 7 firms with a MDT price target in the last 12 months, the median target is $100.
- Current rating
- Perform
- Price target
- $94
- Median target, all firms
- $100
- Actions on MDT
- 4
Oppenheimer price target on MDT
Every Oppenheimer rating on MDT
- Aug 21, 2024
- Nov 23, 2022
- Dec 17, 2021
- Nov 24, 2021
How other firms rate MDT
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Barclays | Equal Weight | $95 | Oct 7, 2026 |
| Needham | Buy | $114 | Aug 27, 2026 |
| UBS | Buy | $100 | Jul 28, 2026 |
| BTIG | Buy | $90 | Jun 4, 2026 |
| Goldman Sachs | Neutral | $84 | May 21, 2026 |
| Citigroup | Buy | $117 | Feb 3, 2026 |
| Wells Fargo | Overweight | $114 | Jan 30, 2026 |
| William Blair | Outperform | Jan 6, 2026 |
Questions about Oppenheimer and MDT
- What is Oppenheimer's price target for MDT?
- Oppenheimer's latest stated price target for Medtronic plc. (MDT) is $94, from its action on Aug 21, 2024.
- What is Oppenheimer's rating on MDT?
- Oppenheimer rates MDT Perform, a neutral rating, as of Aug 21, 2024.
- When did Oppenheimer last change its view on MDT?
- On Aug 21, 2024, Oppenheimer raises its price target to $94 from $92, keeps Perform.
- How does Oppenheimer's MDT target compare with other analysts?
- Across 7 firms with a MDT price target in the last 12 months, the median target is $100.
More MDT rating histories
- Barclays3
- Needham7
- UBS4
- BTIG3
- Goldman Sachs4
- Citigroup6
- Wells Fargo6
- RBC Capital Markets3
- Morgan Stanley4
- Raymond James3
- Truist Securities3
- Credit Suisse3
All Oppenheimer ratingsMDT news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.